Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 5/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769604 | 0.87 | CYP11B1 (0.40) | CYP2A6BMPR1AACVRL1ACVR1BMPR1B | |
| SCHEMBL769159 | 0.86 | CYP11B1 (0.41) | CYP2A6BMPR1AACVRL1ACVR1BMPR1B | |
| SCHEMBL769508 | 0.85 | ACVRL1 (0.38) | CYP2A6BMPR1AACVRL1ACVR1BMPR1B | |
| SCHEMBL769021 | 0.82 | ACVRL1 (0.40) | BMPR1AACVRL1ACVR1BMPR1BCYP11B1 | |
| SCHEMBL768512 | 0.79 | PARP10 (0.54) | CYP2A6CYP11B1CYP11B2PARP10PARP11 | |
| SCHEMBL768920 | 0.77 | ACVRL1 (0.63) | BMPR1AACVRL1ACVR1BMPR1BCYP11B1 | |
| SCHEMBL769027 | 0.77 | CYP11B2 (0.41) | BMPR1AACVRL1ACVR1BMPR1BCYP11B1 | |
| SCHEMBL15869738 | 0.75 | CYP11B2 (0.42) | BMPR1AACVRL1ACVR1BMPR1BCYP11B1 | |
| SCHEMBL15869740 | 0.74 | CYP11B1 (0.39) | BMPR1AACVRL1ACVR1BMPR1BCYP11B1 | |
| SCHEMBL769240 | 0.72 | CYP11B1 (0.41) | BMPR1AACVRL1ACVR1BMPR1BCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| CN-102459223-A | 5-pyridin-3-yl-1, 3-dihydro-indol-2-one derivatives and their use as aldosterone synthase and/or CYP11B1 modulators | NOVARTIS AG | 2012-05-16 | — | — | CN | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| EP-2430011-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130794-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | CYP2A6 44/4885BMPR1A 4080/4885ACVRL1 3179/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | CYP2A6 84/4885BMPR1A 2435/4885ACVRL1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.